News
MREO
3.100
+2.99%
0.090
Weekly Report: what happened at MREO last week (0429-0503)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)
TipRanks · 05/01 10:21
Strong Buy Rating for Mereo Biopharma on Setrusumab’s Promising Phase 3 Progress and Financial Outlook
TipRanks · 05/01 10:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock rose 71.0% to $25.05 during Monday's pre-market session. Koninklijke Philips (NYSE:PHG) shares moved upwards by 40.91%. The company's, Q1 earnings came out today. Akanda and XTL Biopharmaceuticals were the biggest gainers in the market.
Benzinga · 04/29 12:06
Weekly Report: what happened at MREO last week (0422-0426)?
Weekly Report · 04/29 10:34
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 04/24 20:31
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 04/22 20:31
Weekly Report: what happened at MREO last week (0415-0419)?
Weekly Report · 04/22 10:27
BRIEF-Rubric Capital Enters Into Letter Agreement With Mereo Biopharma Group Regarding Cooperation Deal
Rubric Capital Enters Into Letter Agreement With Mereo Biopharma Group Regarding Cooperation Deal. Company says it has entered into a letter agreement with Mereo for a cooperation deal. Mereo is a manufacturer of biopharmaceuticals for the treatment of cancer and other diseases.
Reuters · 04/16 21:58
Weekly Report: what happened at MREO last week (0408-0412)?
Weekly Report · 04/15 10:21
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NASDAQ · 04/12 13:35
Mereo Biopharma Group Plc: A Buy Rating Backed by Strong Leadership and Promising Drug Pipeline
TipRanks · 04/10 10:26
Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham
Dow Jones · 04/10 10:21
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
Benzinga · 04/10 10:11
Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
Seeking Alpha · 04/10 08:08
Weekly Report: what happened at MREO last week (0401-0405)?
Weekly Report · 04/08 10:24
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Dr. Denise Scots-Knight will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024. Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on rare diseases.
Barchart · 04/03 06:30
Weekly Report: what happened at MREO last week (0325-0329)?
Weekly Report · 04/01 10:23
Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Dow Jones · 03/28 14:32
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Benzinga · 03/28 14:22
More
Webull provides a variety of real-time MREO stock news. You can receive the latest news about Mereo Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).